Sociedad Americana de Hirudoterapia

Zāļu valsts aģentūra — State Agency of Medicines of Latvia

ZVA · Latvia · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Latvia's State Agency of Medicines — leeches fall under EU medical-device frameworks (MDR 2017/745) as implemented through Latvian national law; leech-specific national authorisation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Latvia
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Latvian Pharmaceutical Law (Farmācijas likums)
  • EU Medical Device Regulation (MDR) 2017/745 — as transposed into Latvian law
  • Latvian Cabinet of Ministers Regulation No. 689 on Medical Devices

Prescriber Requirements

  • Latvian Health Inspectorate–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

ZVA registration as applicable; Latvian-language labelling required under the State Language Law. Standard cold-chain conditions; EU intra-community movement under MDR applies.

Import/Export Rules

Free movement within the EU single market under MDR; Food and Veterinary Service clearance for live invertebrates from non-EU origin; CITES Appendix II paperwork for Hirudo medicinalis / verbana on extra-EU import.

Reimbursement Context

National Health Service of Latvia (NVD) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general EU MDR framework as transposed into Latvian law. ZVA coordinates with EMA and other EU NCAs; whether leech-specific guidance exists has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.